Binds Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/164.1)
  • Patent number: 9994630
    Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin A. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: June 12, 2018
    Assignee: CANGENE CORPORATION
    Inventors: Jody Berry, Darrell Johnstone, Joyee Antony George, Bonnie Tighe
  • Patent number: 9943583
    Abstract: The invention relates to lipopeptides consisting of a peptide chain comprising a parallel coiled-coil domain, a proline-rich peptide antigen, and a lipid moiety, all covalently linked, which aggregate to synthetic virus-like particles. Proline-rich peptide antigens considered contain negatively and positively charged amino acid, and at least 15% of the amino acids are proline. Such synthetic virus-like particles carrying proline-rich antigens derived from pneumococcal proteins are useful as vaccines against infectious diseases caused by Gram-positive bacteria such as Streptococcus pneumoniae.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: April 17, 2018
    Assignees: UNIVERSITÄT ZÜRICH, SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE, VIROMETIX AG
    Inventors: Arin Ghasparian, Armando Zuniga, Nina Geib, Marco Tamborini, Maja Jud, Gerd Pluschke, Aniebrys Marrero Nodarse, John Anthony Robinson
  • Patent number: 9913875
    Abstract: The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: March 13, 2018
    Assignees: California Institute of Technology, Indi Molecular, Inc.
    Inventors: Blake Farrow, James R. Heath, Heather Dawn Agnew
  • Patent number: 9897606
    Abstract: Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: February 20, 2018
    Inventors: Xuguang Li, Runtao He, Gary Van Domselaar
  • Patent number: 9833528
    Abstract: Methods and compositions for the treatment of biofilms and/or the inhibition of biofilm formation. In one embodiment, a biofilm is treated and/or biofilm formation is inhibited by a method comprising contacting a biofilm or a surface with a bifunctional ligand comprising a quorum-sensing-peptide-binding region and a protease-binding region, whereby the biofilm is treated and/or biofilm formation on the surface is inhibited.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 5, 2017
    Assignee: KCI Licensing, Inc.
    Inventors: Rodolfo M. Alarcon, Amy K. McNulty
  • Patent number: 9492500
    Abstract: Microcin MccPDI and bacteria harboring the mcpM gene which encodes MccPDI, limit growth of and/or kill pathogenic bacteria such as pathogenic Escherichia coli (E. coli) and/or Shigella bacteria via proximity-dependent inhibition (PDl).
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: November 15, 2016
    Assignee: Washington State University
    Inventors: Douglas R. Call, Lauren Eberhart, Kelly A. Brayton, Thomas E. Besser, Ashish Sawant, Lisa Orfe
  • Patent number: 9427462
    Abstract: Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: August 30, 2016
    Assignee: Her Majesty the Queen in Right of Canada As Represented by, the Minister of Health
    Inventors: Xuguang Li, Runtao He, Gary Van Domselaar
  • Patent number: 9387186
    Abstract: Two thiourea derivatives N-(3-chlorophenyl)-N?-(3,4-difluorophenyl)thiourea and N-(3-chlorophenyl)-N-(3-methoxyphenyl)-thiourea are reported as treatment of multidrug resistance infections from Staphylococcus aureus.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: July 12, 2016
    Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Khalid M. Khan, Farzana Naz, Atia-tul Wahab, Atta-ur Rahman
  • Patent number: 9387199
    Abstract: C. difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea. Unfortunately, antibiotic therapy remains as the standard treatment for this antibiotic-induced disease and relapses are common. Antibiotic treatment typically is given for 10 to 14 days for initial or second episode of CDI. For recurrent episodes, more prolonged courses are recommended. It is disclosed herein that lower dose or shorter course of the antimicrobial treatment is sufficient to treat the disease and prevent recurrent disease by enabling a good immunologic response to infection, and perhaps also by better preserving normal flora, thus protecting against relapses or reinfection.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: July 12, 2016
    Assignee: University of Virginia Patent Foundation
    Inventors: Richard L. Guerrant, Cirle Alcantara Warren, John Hudson Moore, II, Edward van Opstal
  • Patent number: 9333250
    Abstract: The present invention relates to methods and compositions for the treatment of bacterial infection, for example extraintestinal E. coli infection such as E. coli bacteremia, meningitis and sepsis. The invention relates also to methods of diagnosis and prevention.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: May 10, 2016
    Assignee: The Johns Hopkins University
    Inventor: Kwang S. Kim
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Publication number: 20150110806
    Abstract: The present invention concerns the use of an inhibitor of an interaction between type IV pilus-associated protein and CD147 for preventing or treating meningoccal bacteraemia and/or infection. The present invention also relates to the combined use of such inhibitor and of an anti-bacterial compound, such as one used to prevent or treat a meningococcal infection. The invention also relates to a method for the prevention and/or treatment of meningococcal bacteraemia and/or infection, and to a method for screening inhibitors of the interaction between type IV pilus-associated protein and CD147.
    Type: Application
    Filed: July 15, 2013
    Publication date: April 23, 2015
    Inventors: Xavier Nassif, Sandrine Bourdoulous, Olivier Join-Lambert
  • Patent number: 9005579
    Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: April 14, 2015
    Assignees: Contrafect Corporation, The Rockfeller University
    Inventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
  • Patent number: 9000131
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: April 7, 2015
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren
  • Publication number: 20150086542
    Abstract: This disclosure provides methods and compositions to inhibit or prevent infection of a cell by a bacteria that exports DNABII proteins by administering to a tissue infected with the bacteria an effective amount of an antibody that specifically recognizes and binds the DNABII proteins, thereby inhibiting or preventing infection of the bacteria. Treatment methods, screens and kits are further provided.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 26, 2015
    Inventors: Steven D. Goodman, Sheryl S. Justice
  • Patent number: 8961977
    Abstract: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: February 24, 2015
    Assignee: University of Rochester
    Inventors: Stephen Dewhurst, Mark A. Sullivan
  • Patent number: 8961975
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: February 24, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
  • Patent number: 8961979
    Abstract: The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: February 24, 2015
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling, Lisa L. Herron Olson
  • Patent number: 8962278
    Abstract: Provided are oligonucleotides for isolating human antibody cDNAs from cells or cell lines, such as hybridomas. The invention also provides cDNAs that encode at least one provided CDR of a heavy chain or a light chain of a human monoclonal antibody that binds to B. anthracis protective antigen; and cDNAs that encode at least one provided CDR of a heavy chain or a light chain of a human monoclonal antibody that binds to B. anthracis lethal factor. The invention further provides expression vectors that contain one or more cDNAs isolated according to the methods of the invention, host cells expressing one or more inventive cDNAs, and transgenic plants and animals that express one or more inventive cDNAs. In certain embodiments of the invention the expression system is a plant-based expression system. The invention further provides antibody compositions comprising one or more antibodies produced by expressing a cDNA isolated according to the methods of the invention in a suitable expression system.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: February 24, 2015
    Assignee: iBio Inc.
    Inventors: Vidadi Yusibov, Vadim Mett, Anna Hull
  • Publication number: 20150050293
    Abstract: High levels of bacterial flagella in a sample such as a gastrointestinal sample and/or low levels of anti-flagella antibodies serve as an indication for metabolic syndrome (such as insulin resistance, hypertension, elevated cholesterol, increased risk for blood clotting, and obesity) with highest levels of adiposity. An intervention that reduces the level and/or activity of flagella in the gastrointestinal tract can mitigate the severity of metabolic syndrome or in protecting against the development of metabolic syndrome.
    Type: Application
    Filed: March 5, 2013
    Publication date: February 19, 2015
    Applicant: CORNELL UNIVERSITY
    Inventors: Ruth E. Ley, Tyler Cullender
  • Publication number: 20150050292
    Abstract: Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against Bacillus anthracis or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused by Bacillus anthracis or other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.
    Type: Application
    Filed: August 14, 2013
    Publication date: February 19, 2015
    Applicants: Board of Regents of th Nevada System of Higher Education, on behalf of the University of Nevada, STC. UNM, Regents of the University of Minnesota
    Inventors: Thomas R. Kozel, William Murphy, Suzanne Brandt, Bruce R. Blazar, Julie A. Lovchik, Peter Thorkildson, Ann Percival, C. Rick Lyons
  • Patent number: 8945568
    Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6D, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?4) ribitol (5?phosphate. This new serotype may be included in pneumococcal vaccines.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: February 3, 2015
    Assignee: The UAB Research Foundation
    Inventors: Moon H. Nahm, In Ho Park
  • Publication number: 20150030613
    Abstract: The invention relates to compositions comprising immunoglobulin for use in the treatment of mucositis by topical application. In particular, the invention relates to compositions comprising J chain-containing IgA and secretory component for the treatment of mucositis.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 29, 2015
    Inventors: Christoph Aebi, Sonja Christina Lueer, Alexander Schaub, Sylvia Miescher, Adrian Zürcher, Cédric Pierre Vonarburg
  • Publication number: 20150023983
    Abstract: The present invention provides a recombinant protein comprising consecutive amino acids, the sequence of which is substantially identical to a sequence of amino acids present in a Rhodococcus equi virulence-associated protein and compositions containing fusion proteins of the invention. The present invention also provides uses of the compositions in the manufacture of hyperimmune plasma against Rhodococcus equi, in producing a hyperimmune plasma against Rhodococcus equi in protecting an animal against Rhodococcus equi and in protecting a newborn animal against Rhodococcus equi.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 22, 2015
    Applicant: SANTA CRUZ BIOTECHNOLOGY, INC.
    Inventor: John R. Stephenson
  • Publication number: 20150010579
    Abstract: The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (VLY) toxin from Gardnerella vaginalis, and biologically active fragments and variants thereof. The invention is also directed to anti-VLY antibodies and to their use therapeutically and in a new ELISA assay of VLY toxin. Other embodiments of the invention are directed to VLY toxoids and to vaccines that use the new VLY toxoids as immunogens.
    Type: Application
    Filed: July 15, 2014
    Publication date: January 8, 2015
    Applicant: The Trustees of the University of Columbia in the City of New York
    Inventor: Adam J. Ratner
  • Patent number: 8926980
    Abstract: Anti-toxin compositions are described that include avian antibodies against bacterial toxins. Administration of the anti-toxin compositions binds and neutralizes the bacterial toxin in the animals. Methods of making the anti-toxin compositions against the bacterial toxins are also described. The anti-toxin compositions can be effective against pathogenic bacteria and also to decrease the amount of bacterial toxins in the individual, especially in the GI tract. The anti-toxin compositions can also act as anti-inflammatory agents.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: January 6, 2015
    Assignee: Camas Incorporated
    Inventors: Bradley M Mitteness, Connie Phillips
  • Patent number: 8916162
    Abstract: Methods and compositions pertaining to botulinum neurotoxin (BoNT) light chain epitopes are provided. In particular, the methods and compositions relate to the use of real and mimetic BoNT light chain epitopes for generating an immune response in a subject, and for immunization against BoNT toxicity. Methods and compositions for detecting, isolating, and purifying BoNT epitopes and anti-BoNT antibodies are also provided.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: December 23, 2014
    Inventor: Alexey Gennadievich Zdanovsky
  • Patent number: 8900824
    Abstract: High affinity antibodies for binding epitopes of BoNT/B and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting BoNT/B in a sample.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: December 2, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Larry H. Stanker, Miles C. Scotcher, Luisa W. Cheng, Robert M. Hnasko, Jeffery A. McGarvey
  • Publication number: 20140350452
    Abstract: The present invention is related to novel functional antibody coated nanoparticles, and the preparation method thereof. The functional antibody coated nanoparticles according to the present invention can be used as photothermal agents to effectively inhibit the growth of microbes including drug-resistant strains and biolfilm with laser irradiation.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 27, 2014
    Inventors: Nancy J. Millenbaugh, Mauris DeSilva, Jonathan Baskin, William R. Elliot
  • Patent number: 8883173
    Abstract: The current invention relates to the diagnosis and treatment of diseases resulting from infections by Mycobacterium avium subsp. paratuberculosis. In particular the invention relates to the use of an antigen selected among (a) a synthetic peptide 5P having the following formula: DPhe-NMeVal-Ile-Phe-Ala-OMe (SEQ ID NO: 1); (b) a lipopeptide L5P consisting of the synthetic peptide a) wherein the N-terminal phenylalanine residue is N-acylated with an eicosanoic acid acyl chain; (c) a variant of peptide a) or lipopeptide b) able to react with anti-Mycobacterium paratuberculosis antibodies; for in vitro detection or quantification of specific anti-Mycobacterium paratuberculosis antibodies in a biological sample.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: November 11, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Institut National de la Recherche Agronomique, Institut Pasteur
    Inventors: Sylvie Bay, Franck Biet
  • Patent number: 8877201
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: November 4, 2014
    Assignee: Wake Forest University Health Sciences
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Patent number: 8877191
    Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: November 4, 2014
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
  • Publication number: 20140271669
    Abstract: The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), are also provided.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicants: Baxter Healthcare SA, Baxter International Inc.
    Inventors: Lucia Hofbauer, Harald Arno Butterweck, Theresa Bauer, Alfred Weber, Wolfgang Teschner, Hans-Peter Schwarz
  • Publication number: 20140271501
    Abstract: The present disclosure relates to methods and compositions administered to the lymphatic tissue of an animal to prevent or reduce the incidence of disease or disease symptoms caused by one or more disease causing entities. Tonsillar compositions can be administered to the lymphatic tissue in the oral/nasal region of the animal and can include avian antibodies from eggs of hens inoculated with one or more target disease causing entities. Treating the lymphatic tissue in the oral/nasal region with the compositions described herein can reduce or prevent the disease causing entities from adhering to the lymphatic tissue resulting in reduced infection rates. The present disclosure also relates to oral compositions that can be used to reduce or eliminate oral pathogens in animals.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Camas Incorporated
    Inventors: Bradley M. Mitteness, Connie Phillips
  • Publication number: 20140271670
    Abstract: Compositions and methods for treating skin disorders including acne vulgaris are disclosed. The composition comprises a neutralizing agent directed against the organism and derivatives associated with the skin disorder, a synergistic agent selected from the group consisting of anti-acne actives, anti-microbial actives, antifungal actives, anti-inflammatory actives, exfoliating agents and mixtures thereof; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: University Medical Pharmaceuticals
    Inventors: Raymond Francis, Gregory Hunt
  • Patent number: 8821879
    Abstract: This invention relates to stable formulations of multiple antibodies comprising a plurality of anti-botulism antibodies and an effective amount of a succinate buffer, an effective amount of arginine, wherein the antibodies are present in substantially equal concentrations and the pH of the formulation is between about 5 and about 6.5.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: September 2, 2014
    Assignee: XOMA Technology Ltd.
    Inventors: Susan Joyce Babuka, Mingxiang Li
  • Patent number: 8821884
    Abstract: The invention provides compositions and methods for the targeted bacteriostatic and antibacterial agents and for treatment of sepsis caused by infectious diseases, such as bacterial and fungal diseases. In one aspect, the invention provides methods and compositions for decreasing the levels of LPS in the circulation of an individual, e.g., a human patient with sepsis, e.g., gram negative septic shock. In one aspect, the invention is directed to chimeric proteins comprising the MD-2 polypeptide and an opsinizing agent, e.g., antibody Fc domains, or equivalent. In one aspect, the invention is directed to chimeric proteins comprising fragments or altered form of MD-2 polypeptide and an opsinizing agent, e.g., antibody Fc domains, or equivalent. The invention also provides pharmaceutical compositions comprising the chimeric polypeptides of the invention, and methods of making and using them, including methods for ameliorating or preventing sepsis.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: September 2, 2014
    Assignee: The Regents of the University of California
    Inventors: Theo N. Kirkland, III, Sunganya Viriyakosol
  • Patent number: 8808699
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant or an antibody directed thereto.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: August 19, 2014
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Alice Cheng, Dominique M. Missiakas, Hwan Keun Kim
  • Patent number: 8784895
    Abstract: The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: July 22, 2014
    Assignee: Northwestern University
    Inventors: Phillip B. Messersmith, Kvar C. L. Black, IV, Ji Yi, Jose G. Rivera
  • Publication number: 20140193429
    Abstract: The present invention relates to an isolated antigen from Streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. The present invention also relates to methods of using the antigen, vaccines, and antibodies of the present invention to detect, treat, and prevent infection and diseases associated with pathogenic bacteria.
    Type: Application
    Filed: March 17, 2014
    Publication date: July 10, 2014
    Applicant: SYRACUSE UNIVERSITY
    Inventors: Robert P. Doyle, Joshua J. Lensbouer
  • Publication number: 20140170164
    Abstract: The present invention provides isolated polypeptides isolatable from a Yersinia spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Application
    Filed: October 8, 2013
    Publication date: June 19, 2014
    Applicant: EPITOPIX, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Laura Wonderling
  • Publication number: 20140161792
    Abstract: The present invention relates to a rhamno-polysaccharide antigen from Enterococcus faecium clonal complex which is useful as a vaccine component for therapy and/or prophylaxis of bacterial infection.
    Type: Application
    Filed: May 25, 2012
    Publication date: June 12, 2014
    Applicants: FORSCHUNGSZENTRUM BORSTEL, UNIVERSIT TSKLINIKUM FREIBURG
    Inventors: Johannes Hübner, Christian Theilacker, Zbignew Kacynski, Otto Holst
  • Patent number: 8748173
    Abstract: The present invention provides monoclonal antibodies which are highly specific for Bacillus spores. Also provided are peptides derived from those monoclonal antibodies. Both the antibodies and peptides are highly specific and can discriminate between spores of potentially lethal organisms such as Bacillus anthracis and other harmless but closely related bacilli and provide a very powerful tool in the construction of detection instruments as counter measures.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: June 10, 2014
    Assignee: UAB Research Foundation
    Inventor: John F. Kearney
  • Publication number: 20140154265
    Abstract: The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes.
    Type: Application
    Filed: September 24, 2013
    Publication date: June 5, 2014
    Inventors: Marjolein Kikkert, Brian Leonard Mark, Puck Bertyne van Kasteren, Terrence William James, Eric John Snijder
  • Publication number: 20140112937
    Abstract: The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.
    Type: Application
    Filed: March 28, 2012
    Publication date: April 24, 2014
    Applicants: FREISTAAT BAYERN REPRESENTED BY JULIUS- -MAXIMILIANS-UNIVERSITAT WURZBURG, MAT-MALTA ADVANCED TECHNOLOGIES LIMITED
    Inventors: Jan Wesjohann, Günter Sprotte, Ana Maria
  • Publication number: 20140099328
    Abstract: Antibody product comprising n-specific antibodies characterized in that a) the n-specific antibodies in each case have an antibody content of at least 6/n % by weight of the total antibody component of the antibody product, and b) 2, 3 or more of the n-specific antibodies target lipopolysaccharide-expressing microorganisms, and c) the total amount of n-specific antibodies is 7% by weight of the total anti-body content of the antibody product.
    Type: Application
    Filed: March 28, 2012
    Publication date: April 10, 2014
    Applicant: MAT-MALTA ADVANCED TECHNOLOGIES LIMITED
    Inventor: Jan Wesjohann
  • Publication number: 20140093518
    Abstract: Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound.
    Type: Application
    Filed: August 26, 2013
    Publication date: April 3, 2014
    Applicant: The Scripps Research Institute
    Inventor: Carlos F. Barbas, III
  • Publication number: 20140065195
    Abstract: The present invention encompasses methods and compositions for Ureaplasma infection prevention and/or treatment. In specific cases, the invention concerns vaccines for Ureaplasma, including DNA vaccines. In certain embodiments, the invention regards vaccines directed towards the multiple-banded antigen(s) of Ureaplasma.
    Type: Application
    Filed: April 30, 2012
    Publication date: March 6, 2014
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Leonard Weisman, Lingkun Kong
  • Publication number: 20140050741
    Abstract: The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.
    Type: Application
    Filed: February 17, 2012
    Publication date: February 20, 2014
    Applicants: UNIVERSITEIT LEIDEN, UNIVERSITÄTSKLINIKUM FREIBURG
    Inventors: Johannes Huebner, Andrea Huebner-Kropec, Jeroen Dirk Cornelis Codée, Gijsbert Arie Van Der Marel, Wouter Frederick Johan Hogendorf
  • Publication number: 20140037649
    Abstract: Disclosed are methods and apparatus for diagnosis, detection of host response, monitoring, treatment or management of sepsis, infection-negative systemic inflammatory response syndrome (SIRS) and post-surgical inflammation in mammals. More particularly, the present invention discloses marker genes and their splice variant transcripts as well as their expression products, which are useful for distinguishing between sepsis and infection-negative SIRS, including post-surgical inflammation, and to the use of these markers in grading, monitoring, treatment and management of these conditions.
    Type: Application
    Filed: November 24, 2011
    Publication date: February 6, 2014
    Applicant: IMMUNEXPRESS PTY LTD
    Inventors: Richard Bruce Brandon, Mervyn Rees Thomas, Glenn Stone